In the latest session, Coherus BioSciences Inc. (NASDAQ: CHRS) closed at $4.53 down -7.93% from its previous closing price of $4.92. In other words, the price has decreased by -$0.3900 from its previous closing price. On the day, 4036254 shares were traded. CHRS stock price reached its highest trading level at $4.8700 during the session, while it also had its lowest trading level at $4.3700.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
Ratios:
For a deeper understanding of Coherus BioSciences Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on July 24, 2023, initiated with a Buy rating and assigned the stock a target price of $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 481.95M and an Enterprise Value of 816.49M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.57. Its current Enterprise Value per Revenue stands at 4.49 whereas that against EBITDA is -3.65.
Stock Price History:
Over the past 52 weeks, CHRS has reached a high of $10.99, while it has fallen to a 52-week low of $3.60. The 50-Day Moving Average of the stock is 4.7036, while the 200-Day Moving Average is calculated to be 6.2716.
Shares Statistics:
For the past three months, CHRS has traded an average of 3.50M shares per day and 5.34M over the past ten days. A total of 106.39M shares are outstanding, with a floating share count of 101.84M. Insiders hold about 1.61% of the company’s shares, while institutions hold 92.78% stake in the company. Shares short for CHRS as of Aug 30, 2023 were 15.65M with a Short Ratio of 15.65M, compared to 13.45M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 16.57% and a Short% of Float of 20.59%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.29 for the current quarter, with a high estimate of $0.03 and a low estimate of -$0.67, while EPS last year was -$0.96. The consensus estimate for the next quarter is -$0.05, with high estimates of $0.25 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.8 and -$2.06 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is $0.22, with 7 analysts recommending between $0.8 and -$0.46.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $83.56M this quarter.It ranges from a high estimate of $96M to a low estimate of $75M. As of the current estimate, Coherus BioSciences Inc.’s year-ago sales were $56.91M, an estimated increase of 46.80% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $112.63M, an increase of 148.30% over than the figure of $46.80% in the same quarter last year. There is a high estimate of $132M for the next quarter, whereas the lowest estimate is $101.34M.
A total of 9 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $303.65M, while the lowest revenue estimate was $275.99M, resulting in an average revenue estimate of $288.91M. In the same quarter a year ago, actual revenue was $211.04M, up 36.90% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $522.48M in the next fiscal year. The high estimate is $674M and the low estimate is $392.05M. The average revenue growth estimate for next year is up 80.80% from the average revenue estimate for this year.